Advarra

AUGUST 8, 2023

Gene therapy research is booming in the clinical setting. In this blog, we summarize the growth, risks, and regulatory requirements for gene therapy research. Defining the Boom in Gene Therapy Research The gene therapy field is experiencing explosive growth in today’s competitive research environment.

Therapies 52

Therapies Research Engineering Clinical Research 52

The Pharma Data

MARCH 23, 2022

To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives.

Virus 52

Virus Small Molecule Protein Production Research 52

The Pharma Data

JANUARY 4, 2021

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. 05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. MUNICH, Germany, Jan.

Therapies 52

Therapies Virus Disease Licensing 52

Alta Sciences

OCTOBER 7, 2024

Latest Findings in Gene Therapy Research blussier Mon, 10/07/2024 - 15:16 HTML A Promising Future for Gene Therapy Our experts have been diligently working on groundbreaking research, including a wide range of gene therapy studies, and have compiled a selection of scientific resources featuring the latest advancements.

Therapies 40

Therapies Research Laboratories Virus 40

DrugBank

MARCH 12, 2025

  The Expanding Role of mRNA in Cancer Therapy One of the most exciting applications of mRNA therapeutics lies in cancer treatment, where leveraging the immune system to target tumors offers a novel approach. These findings underscore the potential of mRNA to redefine cancer treatment by offering precise, patient-specific therapies.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

Licensing 52

Licensing Licensing Therapies Disease 52

The Pharma Data

JANUARY 18, 2021

Use of AAVnerGene capsid library provided to Neurophth for ophthalmic gene therapy. Next Generation AAVs enhance gene therapies by increasing transduction efficiency and specificity while reducing immune responses and cost. gene therapy company (hereafter Neurophth), and AAVnerGene Inc. ,

Therapies 52

Therapies Immune Response DNA Treatment 52

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. INDIANAPOLIS and THOUSAND OAKS, Calif.

Therapies 52

Therapies Production Government Disease 52

PLOS: DNA Science

FEBRUARY 8, 2024

They write: “Genome engineering of probiotics, including the editing of the genome to introduce, remove, or modify phenotypes, will improve their tolerance to stress during food production, promote their survival in the gastrointestinal tract, or enhance their probiotic function. But will it, can it, improve upon nature?

Immune Response 97

Immune Response DNA Engineering Virus 97

Drug Target Review

SEPTEMBER 28, 2023

After some time in that role and launching several products, I received a call from Bill Banyai and Bill Peck, or ‘The Bills’ as we call them, who were building a company around technology that creates DNA by ‘writing’ it on a silicon chip. These are synthetic, not the live virus, so do not pose a risk of infection.

DNA 116

DNA Organic Chemistry Science Virus 116

The Pharma Data

JANUARY 3, 2021

(Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that U.S. GM1 is a rare and often life-threatening CNS disorder with no approved disease-modifying therapies available. About PBGM01. About Passage Bio.

Therapies 52

Therapies FDA Treatment Clinical Trials 52

The Pharma Data

JANUARY 27, 2021

– Second Product Candidate Expected to Enter Clinic in First Half of 2021. Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a Devastating, Progressive Disorder Impacting Adults with No Approved Disease-Modifying Therapy Options. PHILADELPHIA, Jan.

Therapies 52

Therapies Clinical Trials Treatment FDA 52

Agency IQ

FEBRUARY 12, 2024

BY RACHEL COE, MSC | FEB 7, 2024 10:21 PM CST The Bespoke Gene Therapy Consortium A collaborative effort, the Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021 to “accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease.”

FDA 40

FDA Therapies Clinical Trials Disease 40

The Pharma Data

FEBRUARY 22, 2021

State Premier of North Rhine-Westphalia Armin Laschet and Birgitta Radermacher, President of Duesseldorf Administrative District, today visited Bayer AG’s research and production site in Wuppertal to gain an insight into the planned vaccine production there. Effective vaccines are our best weapon to combat the pandemic. About Bayer.

Vaccine 40

Vaccine Production Virus Pharmaceuticals 40

The Pharma Data

OCTOBER 28, 2020

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

OCTOBER 21, 2020

In the midst of the global pandemic, the analysis found no antiretroviral therapy interruptions across the entirety of the ongoing clinical development programme for long-acting cabotegravir and rilpivirine. Of those participants who transitioned back to injectables, the median duration of oral therapy was 51 days.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

Drug Target Review

APRIL 17, 2024

HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production. HLA-I molecules present peptides to CD8 T cells and are thought to be responsible for direct recognition and killing of cells with foreign viruses, bacteria, or oncogenic cancer cells.

Immune Response 105

Immune Response Laboratories DNA Virus 105

Fierce BioTech

JULY 17, 2023

Sponsors are faced with a stark learning curve that, without intervention, may lead to high costs, delays, and a failure to bring their drug to patients. Sponsors are faced with a stark learning curve that, without intervention, may lead to high costs, delays, and a failure to bring their drug to patients.

Clinical Trials 52

Clinical Trials Virus Trials Therapies 52

The Pharma Data

JANUARY 31, 2021

Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. About Dynavax. About GlaxoSmithKline.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

DECEMBER 17, 2020

About casirivimab and imdevimab Casirivimab and imdevimab (formerly known as REGN-COV2 or REGEN-COV2) is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. who require oxygen therapy due to COVID-19, OR.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

AUGUST 18, 2020

Experts suspect this is because the pandemic virus attacks nerve cells directly involved with smell and taste sensation. Anyone with these symptoms should self-isolate and arrange to have a swab test to check if they have the virus. The nose is one of the places where Sars-CoV-2, the virus that causes Covid-19, enters the body.

Virus 52

Virus Science Therapies Research 52

The Pharma Data

JANUARY 19, 2021

A naturally occurring system for tuning CRISPR-Cas9 expressing in bacteria, identified in a study published in Cell , could have implications for gene editing therapies as well. In particular, Editas is known to be exploring tunable CRISPR-Cas9 systems for therapies has developed self-inactivating Cas9 adeno-associated virus vectors.

Research 52

Research RNA Molecular Biology Small Molecule 52

The Pharma Data

DECEMBER 3, 2020

Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. Trimer-Tag © is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

AUGUST 7, 2020

As the pharma industry stands firm in its commitment to advance the sector to fight Covid-19, news has emerged from the European Commission who intend to streamline the development of therapies using genetically modified organisms to treat Covid-19. Regenerative medicine and advanced therapies thriving despite Covid-19 disruption.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

JANUARY 21, 2021

Cabotegravir is a ViiV product marketed as Cabenuva, and rilpivirine is a Janssen product with a brand name Edurant. The once-a-month regimen was preferred by nine out of 10 patients over the daily oral therapy. Food and Drug Administration (FDA) gave a greenlight for ViiV Healthcare ’s Cabenuva. clinical practices.

FDA Approval 52

FDA Approval Treatment FDA Clinical Trials 52

The Pharma Data

JANUARY 31, 2021

Clover expects to produce hundreds of millions of vaccine doses in 2021 and up to 1 billion vaccine doses in peak annual production as required by global demand. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

DECEMBER 31, 2020

Taysha Gene Therapies – Texas-based Taysha Gene Therapies bolstered its leadership team with the appointments of Greg Gara as senior vice president of Manufacturing and Kimberly Lee as senior vice president of Corporate Communications and Investor Relations. He is currently the CEO of BlockchainK2 Corp., Source link.

Engineering 52

Engineering Pharmaceuticals Clinical Development Virus 52

The Pharma Data

APRIL 15, 2022

These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group. The neutralizing GMT against the wild-type virus was 2153 (after three doses), compared to 335 after two doses. About Pfizer: Breakthroughs That Change Patients’ Lives.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

OCTOBER 6, 2021

Pfizer and BioNTech today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies’ COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18?years years of age and older.

Vaccine 52

Vaccine Small Molecule Government Therapies 52

The Pharma Data

OCTOBER 27, 2021

The scientists are confident of the efficiency of the new product. “The main finding in our study is that the equine hyperimmune globulins antibodies developed against the spike protein of the ancestral SARS-CoV-2 had high neutralizing action against the new variants of the virus, such as the gamma strain. .

Clinical Trials 52

Clinical Trials Virus Production Treatment 52

The Pharma Data

NOVEMBER 5, 2020

5 of its ongoing Phase 2 extension study, Study 211, examining vebicorvir (VBR, or ABI-H0731) in patients with hepatitis B virus infection. The company’s other two Phase 2 trials, Study 201 and 202, showed that the addition of VBR to NrtI therapy achieved a quicker, deeper level of viral suppression than with NrtI alone.

Virus 40

Virus Clinical Trials Therapies Pharmacokinetics 40

Alta Sciences

JULY 25, 2024

38 Ensuring Successful Formulation and Drug Product Manufacture for Preclinical Testing Preclinical manufacturing involves various critical sub-processes, from formulation development and manufacturing, to stability studies and process validation. the UK, or the EU. Read the eBook. View the podcast. The Altascientist: Issue No.

Science 52

Science Clinical Trials Clinical Pharmacology FDA 52

The Pharma Data

NOVEMBER 22, 2020

The ultra-cold storage needed for the Pfizer-BioNTech product is not unprecedented. They use mRNA that codes for the spike protein in the SARS-CoV-2 virus, which is embedded in a nanolipid particle—basically a minuscule fat molecule. Both the Pfizer-BioNTech and Moderna vaccines utilize mRNA technology. Featured Jobs on BioSpace.

Vaccine 52

Vaccine Virus Trials Regulations 52

The Pharma Data

OCTOBER 26, 2020

Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. SAN JOSE, Calif. , AR-711 (COVID-19).

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

NOVEMBER 1, 2020

The BD Veritor Plus System is already in use across Europe to detect Influenza A+B, Respiratory Syncytial Virus (RSV), and Group A Strep. For Product Enquiries and How to Order: All BD SARS-CoV-2 diagnostic products have regulatory authorizations in the markets where they are sold. Food and Drug Administration (FDA).

Laboratories 52

Laboratories Virus FDA Government 52